ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010
Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.Breast cancer research and treatment · 2014Article
- A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.BMJ open · 2014Article
- The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study.British journal of cancer · 2013Article
- Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality.British journal of cancer · 2013Article
- Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing.Journal of personalized medicine · 2012Article
- Recent progress and clinical importance on pharmacogenetics in cancer therapy.Clinical chemistry and laboratory medicine · 2011Review
- Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory?Journal of general internal medicine · 2011Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
20921464What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.